Judge Upset 'Entire Balance' Of Biosimilar Law, Amgen Says
A federal judge threatened "the entire balance" of the Biologics Price Competition and Innovation Act by allowing Hospira to withhold manufacturing information about a proposed biosimilar that may infringe patents, Amgen...To view the full article, register now.
Already a subscriber? Click here to view full article